Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 4:33 PM ET
Nektar Therapeutics (NKTR) Statistics
Nektar Therapeutics (NKTR) has a market cap of $1.25B and an enterprise value of $1.21B. Its share count is up 80.39% from a year earlier. It kept -339.67% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 2.78% below the market cap, as cash exceeds debt.
| Market Cap | $1.25B |
|---|---|
| Enterprise Value | $1.21B |
| Latest price (Nov 17, 2026) | $35.91 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 23.5x and 1.4x. Its year-end P/S ranged from 1.2x to 40.8x from 2016 to 2025.
| P/S Ratio | 23.5x |
|---|---|
| Forward P/S | 30.4x |
| P/B Ratio | 1.4x |
Price Statistics
The stock is down 36.64% over 52 weeks and trades 23.48% below its 50-day average.
| Beta (1Y) | 1.06 |
|---|---|
| 52-Week Change | -36.64% |
| 1-Month Change | -1.99% |
| 3-Month Change | -52.80% |
| 6-Month Change | -46.86% |
| 5-Year Change | -82.90% |
| 10-Year Change | -79.09% |
| Total Return (1Y) | -36.64% |
| Total Return (3Y CAGR) | +70.66% |
| Total Return (5Y CAGR) | -27.28% |
| Return vs SPY (1Y) | -50.87% |
| Max Drawdown (1Y) | -64.34% |
| Max Drawdown (3Y) | -73.20% |
| Sharpe Ratio (1Y) | -0.64 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $46.93 |
| 200-Day Average | $65.04 |
| 52-Week Range | $33.40 to $109.00 |
| RSI (14 Days) | 34.4 |
| Average Volume (20 Days) | 625.94K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.00x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.00x |
|---|---|
| Quick Ratio | 9.00x |
| Debt / Equity | 0.00x |
| Interest Coverage | -5.28x |
Returns and Efficiency
Return on equity is -20.86% and return on assets is -17.09% over the last 12 months.
| Return on Equity (ROE) | -20.86% |
|---|---|
| Return on Assets (ROA) | -17.09% |
| Return on Capital Employed (ROCE) | -17.41% |
| ROA (5Y Average) | -53.14% |
| Asset Turnover | 0.08x |
Scores
NKTR has an Altman Z-Score of -1.12, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $52.19M over the last 12 months is down 16.64% from the 12 months before.
| Revenue | $52.19M |
|---|---|
| Revenue Growth (YoY) | -16.64% |
| Gross Profit | $52.19M |
| Operating Income | -$166.86M |
| Pretax Income | -$173.14M |
| Net Income | -$177.26M |
| EBIT | -$167.40M |
| Reported EPS (TTM) | -$6.42 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 81.70% of the $1.04B in total assets.
| Cash and Equivalents | $34.69M |
|---|---|
| Total Debt | $0 |
| Net Cash | $34.69M |
| Net Cash Per Share | $1.01 |
| Working Capital | $603.86M |
| Shareholder Equity | $849.72M |
| Book Value Per Share | $24.86 |
| Total Assets | $1.04B |
| Total Liabilities | $187.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $528.00K of capital spending, operating cash flow left -$257.49M of free cash flow.
| Operating Cash Flow | -$256.96M |
|---|---|
| Capital Expenditures | $528.00K |
| Free Cash Flow | -$257.49M |
| FCF Per Share | -$7.54 |
| Depreciation and Amortization | $11.31M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -319.75%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -319.75% |
| Pretax Margin | -331.78% |
| Net Margin | -339.67% |
| EBIT Margin | -320.78% |
| FCF Margin | -493.41% |
| Gross Margin (5Y Average) | 76.68% |
Growth
Revenue fell 15.66% a year over 3 years.
| Revenue Growth (3Y CAGR) | -15.66% |
|---|---|
| Revenue Growth (5Y CAGR) | -18.43% |
| Book Value Per Share Growth (2Y CAGR) | -34.40% |
| Tangible Book Per Share Growth (2Y CAGR) | -34.40% |
Dividends and Yields
NKTR does not pay a dividend. Its free cash flow yield is -20.98%.
| FCF Yield | -20.98% |
|---|---|
| Buyback Yield | -76.04% |
| Shareholder Yield | -76.04% |
Stock Splits
The last split was a 1-for-15 reverse split on Jun 9, 2025.
| Last Split Date | Jun 9, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 10 similar companies, NKTR has the 4th highest P/S.
P/S RatioPeer median 13.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.80%
| P/S Ratio | 23.5x vs 13.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -16.64% vs +15.80% median |
Analyst Forecast
Consensus estimates put revenue growth at 0.01% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +0.01% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NKTR
What is NKTR's market cap?
Nektar Therapeutics has a market cap of $1.25B. Its enterprise value, which adds debt and subtracts cash, is $1.21B.
How many shares of NKTR are outstanding?
Nektar Therapeutics has 34.18M shares outstanding. The count is up 80.39% from a year earlier.
Does NKTR pay a dividend?
No. Nektar Therapeutics does not pay a dividend.
How much debt does NKTR have?
Nektar Therapeutics has $0 of total debt and $34.69M of cash and equivalents, a net cash position of $34.69M.
NKTR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors